Journey Through the Thymus: Stromal Guides for T-Cell Development and Selection
Total Page:16
File Type:pdf, Size:1020Kb
Load more
Recommended publications
-
Horse Gamma Globulin Stabilized in 0.3 Molar Glycine to a Ph of Approximately 6.8
LPD Reference: ATG-SIN-0414/1 Date of Last Revision: 08 September 2014 Country: Singapore Reference document: CDS Version 3.0, effective date: 17-Mar-2014 Reason for change: LPD update in accordance with CDS 3.0 ; 2014-09-08 IR: 1. Remove entire proposed subsection <Renal Transplant Prophylaxis> under ‘Pharmacodynamic Properties - Clinical Studies’ & 2. Relocate paragraph “Clinical trials […] standard supportive care alone” from <Therapeutic Indications> to < Pharmacodynamic Properties - Clinical Studies>, subsection <Aplastic Anemia>. Atgam® lymphocyte immune globulin, anti-thymocyte globulin [equine] sterile solution For Intravenous Use only DESCRIPTION ATGAM Sterile Solution contains lymphocyte immune globulin, anti-thymocyte globulin [equine]. It is the purified, concentrated, and sterile gamma globulin, primarily monomeric IgG, from hyperimmune serum of horses immunized with human thymus lymphocytes. Anti-thymocyte globulin (equine) is a transparent to slightly opalescent aqueous protein solution. It may appear colorless to faintly pink or brown and is nearly odorless. It may develop a slight granular or flaky deposit during storage. (For information about in-line filters, see Infusion Instructions in the POSOLOGY AND METHOD OF ADMINISTRATION.) Before release for clinical use, each lot of anti-thymocyte globulin (equine) is tested to assure its ability to inhibit rosette formation between human peripheral lymphocytes and sheep red blood cells in vitro. In each lot, antibody activity against human red blood cells and platelets is also measured and determined to be within acceptable limits. Only lots that test negative for antihuman serum protein antibody, antiglomerular basement membrane antibody and pyrogens are released. Each milliliter of anti-thymocyte globulin (equine) contains 50 mg of horse gamma globulin stabilized in 0.3 molar glycine to a pH of approximately 6.8. -
Our Immune System (Children's Book)
OurOur ImmuneImmune SystemSystem A story for children with primary immunodeficiency diseases Written by IMMUNE DEFICIENCY Sara LeBien FOUNDATION A note from the author The purpose of this book is to help young children who are immune deficient to better understand their immune system. What is a “B-cell,” a “T-cell,” an “immunoglobulin” or “IgG”? They hear doctors use these words, but what do they mean? With cheerful illustrations, Our Immune System explains how a normal immune system works and what treatments may be necessary when the system is deficient. In this second edition, a description of a new treatment has been included. I hope this book will enable these children and their families to explore together the immune system, and that it will help alleviate any confusion or fears they may have. Sara LeBien This book contains general medical information which cannot be applied safely to any individual case. Medical knowledge and practice can change rapidly. Therefore, this book should not be used as a substitute for professional medical advice. SECOND EDITION COPYRIGHT 1990, 2007 IMMUNE DEFICIENCY FOUNDATION Copyright 2007 by Immune Deficiency Foundation, USA. Readers may redistribute this article to other individuals for non-commercial use, provided that the text, html codes, and this notice remain intact and unaltered in any way. Our Immune System may not be resold, reprinted or redistributed for compensation of any kind without prior written permission from Immune Deficiency Foundation. If you have any questions about permission, please contact: Immune Deficiency Foundation, 40 West Chesapeake Avenue, Suite 308, Towson, MD 21204, USA; or by telephone at 1-800-296-4433. -
Visualizing B Cell Development: Creating an Immunology Video Game
VISUALIZING B CELL DEVELOPMENT: CREATING AN IMMUNOLOGY VIDEO GAME By Emily Lunhui Ling A thesis submitted to Johns Hopkins University in conformity with the requirements for the degree of Master of Arts Baltimore, Maryland March, 2016 © 2016 Emily L. Ling All Rights Reserved ABSTRACT e foundational immunology concepts of lymphocyte development are important for beginning science students to comprehend. Video games oer the potential for a novel approach to teaching this complex subject matter by more eectively engaging students in this material. However, currently available educational video games intended to teach immunology have distinct limitations such as a lack of explicit demonstrations of the stages of lymphocyte development and clonal selection. is project identies the content focus and gameplay mechanics of currently available immunology video games. Using this as a basis, a novel approach for developing an immunology video game was outlined with the primary goal of improving integration of educational content. A proof of concept was developed for the B lymphocyte development portion of the game content and a partial prototype was developed in Unity 5 3D. e important contribution of this thesis was the development of a new approach to designing a more eective educational video game specically for immunology. Outcomes of this research will serve to inform future biomedical communicators on how to develop content for active learning games in immunology and provide a guide for designing full length educational video games featuring novel gameplay mechanics such as those identied through this project. Emily L. Ling ii CHAIRPERSONS OF THE SUPERVISORY COMMITTEE esis Preceptor Mark J. Soloski, Ph.D., Professor of Medicine Departments of Medicine, Pathology, Molecular Biology and Genetics, and Molecular Microbiology and Immunology Director, Immunology Training Program e Johns Hopkins University School of Medicine Departmental Advisor David A. -
Review Article Mesenchymal Stromal Cells Affect Disease Outcomes Via Macrophage Polarization
View metadata, citation and similar papers at core.ac.uk brought to you by CORE provided by Crossref Hindawi Publishing Corporation Stem Cells International Volume 2015, Article ID 989473, 11 pages http://dx.doi.org/10.1155/2015/989473 Review Article Mesenchymal Stromal Cells Affect Disease Outcomes via Macrophage Polarization Guoping Zheng,1 Menghua Ge,1 Guanguan Qiu,1 Qiang Shu,2 and Jianguo Xu1,3 1 Shaoxing Second Hospital, Shaoxing, Zhejiang 312000, China 2The Children’s Hospital of Zhejiang University School of Medicine, Hangzhou, Zhejiang 310052, China 3The First Affiliated Hospital of Zhejiang University School of Medicine, Hangzhou, Zhejiang 310003, China Correspondence should be addressed to Jianguo Xu; [email protected] Received 18 May 2015; Accepted 30 June 2015 Academic Editor: Armand Keating Copyright © 2015 Guoping Zheng et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. Mesenchymal stromal cells (MSCs) are multipotent and self-renewable cells that reside in almost all postnatal tissues. In recent years, many studies have reported the effect of MSCs on the innate and adaptive immune systems. MSCs regulate the proliferation, activation, and effector function of T lymphocytes, professional antigen presenting cells (dendritic cells, macrophages, and B lymphocytes), and NK cells via direct cell-to-cell contact or production of soluble factors including indoleamine 2,3-dioxygenase, prostaglandin E2, tumor necrosis factor- stimulated gene/protein 6, nitric oxide, and IL-10. MSCs are also able to reprogram macrophages from a proinflammatory M1 phenotype toward an anti-inflammatory M2 phenotype capable of regulating immune response. -
FOXN1 Deficiency: from the Discovery to Novel Therapeutic Approaches
CORE Metadata, citation and similar papers at core.ac.uk Provided by Archivio della ricerca - Università degli studi di Napoli Federico II J Clin Immunol DOI 10.1007/s10875-017-0445-z CME REVIEW FOXN1 Deficiency: from the Discovery to Novel Therapeutic Approaches Vera Gallo1 & Emilia Cirillo1 & Giuliana Giardino1 & Claudio Pignata1 Received: 29 June 2017 /Accepted: 11 September 2017 # Springer Science+Business Media, LLC 2017 Abstract Since the discovery of FOXN1 deficiency, the hu- cellular and humoral immunity. To date, more than 20 genetic man counterpart of the nude mouse, a growing body of evi- alterations have been identified as responsible for the disease dence investigating the role of FOXN1 in thymus and skin, [1]. Among these, the FOXN1 gene mutation, causative of the has been published. FOXN1 has emerged as fundamental for nude SCID phenotype, is the unique condition in which the thymus development, function, and homeostasis, representing immunological defect is related to an alteration of the thymic the master regulator of thymic epithelial and T cell develop- epithelial stroma and not to an intrinsic defect of the hemato- ment. In the skin, it also plays a pivotal role in keratinocytes poietic cell. The nude SCID phenotype has been identified in and hair follicle cell differentiation, although the underlying human for the first time in 1996 in two female patients who molecular mechanisms still remain to be fully elucidated. The presented with thymus aplasia and ectodermal abnormalities nude severe combined immunodeficiency phenotype is in- [2], approximately 30 years later than the initial description of deed characterized by the clinical hallmarks of athymia with the murine counterpart. -
Reactive Stroma in Human Prostate Cancer: Induction of Myofibroblast Phenotype and Extracellular Matrix Remodeling1
2912 Vol. 8, 2912–2923, September 2002 Clinical Cancer Research Reactive Stroma in Human Prostate Cancer: Induction of Myofibroblast Phenotype and Extracellular Matrix Remodeling1 Jennifer A. Tuxhorn, Gustavo E. Ayala, Conclusions: The stromal microenvironment in human Megan J. Smith, Vincent C. Smith, prostate cancer is altered compared with normal stroma and Truong D. Dang, and David R. Rowley2 exhibits features of a wound repair stroma. Reactive stroma is composed of myofibroblasts and fibroblasts stimulated to Departments of Molecular and Cellular Biology [J. A. T., T. D. D., express extracellular matrix components. Reactive stroma D. R. R.] and Pathology [G. E. A., M. J. S., V. C. S.] Baylor College of Medicine, Houston, Texas 77030 appears to be initiated during PIN and evolve with cancer progression to effectively displace the normal fibromuscular stroma. These studies and others suggest that TGF-1isa ABSTRACT candidate regulator of reactive stroma during prostate can- Purpose: Generation of a reactive stroma environment cer progression. occurs in many human cancers and is likely to promote tumorigenesis. However, reactive stroma in human prostate INTRODUCTION cancer has not been defined. We examined stromal cell Activation of the host stromal microenvironment is pre- phenotype and expression of extracellular matrix compo- dicted to be a critical step in adenocarcinoma growth and nents in an effort to define the reactive stroma environ- progression (1–5). Several human cancers have been shown to ment and to determine its ontogeny during prostate cancer induce a stromal reaction or desmoplasia as a component of progression. carcinoma progression. However, the specific mechanisms of Experimental Design: Normal prostate, prostatic intra- stromal cell activation are not known, and the extent to which epithelial neoplasia (PIN), and prostate cancer were exam- stroma regulates the biology of tumorigenesis is not fully un- ined by immunohistochemistry. -
1-Phosphate-Lyase-Deficient Mice Development in Sphingosine
Discontinued Postnatal Thymocyte Development in Sphingosine 1-Phosphate-Lyase-Deficient Mice This information is current as Claudia Weber, Andreas Krueger, Anika Münk, Constantin of October 1, 2021. Bode, Paul P. Van Veldhoven and Markus H. Gräler J Immunol 2009; 183:4292-4301; Prepublished online 11 September 2009; doi: 10.4049/jimmunol.0901724 http://www.jimmunol.org/content/183/7/4292 Downloaded from Supplementary http://www.jimmunol.org/content/suppl/2009/09/10/jimmunol.090172 Material 4.DC1 http://www.jimmunol.org/ References This article cites 48 articles, 20 of which you can access for free at: http://www.jimmunol.org/content/183/7/4292.full#ref-list-1 Why The JI? Submit online. • Rapid Reviews! 30 days* from submission to initial decision • No Triage! Every submission reviewed by practicing scientists by guest on October 1, 2021 • Fast Publication! 4 weeks from acceptance to publication *average Subscription Information about subscribing to The Journal of Immunology is online at: http://jimmunol.org/subscription Permissions Submit copyright permission requests at: http://www.aai.org/About/Publications/JI/copyright.html Email Alerts Receive free email-alerts when new articles cite this article. Sign up at: http://jimmunol.org/alerts The Journal of Immunology is published twice each month by The American Association of Immunologists, Inc., 1451 Rockville Pike, Suite 650, Rockville, MD 20852 Copyright © 2009 by The American Association of Immunologists, Inc. All rights reserved. Print ISSN: 0022-1767 Online ISSN: 1550-6606. The Journal of Immunology Discontinued Postnatal Thymocyte Development in Sphingosine 1-Phosphate-Lyase-Deficient Mice1,2 Claudia Weber,3* Andreas Krueger,3* Anika Mu¨nk,* Constantin Bode,* Paul P. -
Type 3 Innate Lymphoid Cells a Stromal Cell Niche for Human and Mouse
A Stromal Cell Niche for Human and Mouse Type 3 Innate Lymphoid Cells Kerim Hoorweg, Priyanka Narang, Zhi Li, Anne Thuery, Natalie Papazian, David R. Withers, Mark C. Coles and Tom This information is current as Cupedo of September 28, 2021. J Immunol 2015; 195:4257-4263; Prepublished online 16 September 2015; doi: 10.4049/jimmunol.1402584 http://www.jimmunol.org/content/195/9/4257 Downloaded from References This article cites 42 articles, 9 of which you can access for free at: http://www.jimmunol.org/content/195/9/4257.full#ref-list-1 http://www.jimmunol.org/ Why The JI? Submit online. • Rapid Reviews! 30 days* from submission to initial decision • No Triage! Every submission reviewed by practicing scientists • Fast Publication! 4 weeks from acceptance to publication by guest on September 28, 2021 *average Subscription Information about subscribing to The Journal of Immunology is online at: http://jimmunol.org/subscription Permissions Submit copyright permission requests at: http://www.aai.org/About/Publications/JI/copyright.html Email Alerts Receive free email-alerts when new articles cite this article. Sign up at: http://jimmunol.org/alerts The Journal of Immunology is published twice each month by The American Association of Immunologists, Inc., 1451 Rockville Pike, Suite 650, Rockville, MD 20852 Copyright © 2015 by The American Association of Immunologists, Inc. All rights reserved. Print ISSN: 0022-1767 Online ISSN: 1550-6606. The Journal of Immunology A Stromal Cell Niche for Human and Mouse Type 3 Innate Lymphoid Cells Kerim Hoorweg,*,1 Priyanka Narang,†,1 Zhi Li,† Anne Thuery,† Natalie Papazian,* David R. -
Tumor Microenvironment Consortium
Tumor Microenvironment Network (TMEN) Dinah Singer, Ph.D. Director Suresh Mohla, Ph.D. TMEN Program Director Division of Cancer Biology TMEN 2006-2011: Goals – Generate a comprehensive understanding of the composition of the normal stroma and the role of the stroma in tumor initiation, progression and metastasis – Develop resources and infrastructure critical to the broader research community to advance understanding of the tumor microenvironment (TME) TMEN 2006-2011: Current Program •Nine interdisciplinary groups characterizing the TME in major cancer sites, emphasizing human samples •Identifying and translating promising leads •Collaboratively addressing the complexity of TME by assessing: • The co-evolution of tumor-associated stromal cell types and the tumor •Stromal cell interactions with each other and with tumor cells •Generating novel reagents, models and technologies for the research community TMEN 2006-2011: Areas of Emphasis Microenvironment Initiation Progression Metastasis – Tumor initiating cells – Tumor heterogeneity – Stromal cell types and cellular processes – Complex signaling pathways – Genes and genetics TMEN 2006-2011: Scientific Accomplishments Tumor Initiating Cells: • Combined invasive gene signatures in tumor initiating cells and stromal wound repair response genes robustly predict metastasis-free and overall survival in breast, medulloblastoma, lung and prostate cancer patients • New therapeutic approaches to circumvent the chemo- and radio-resistance of tumor initiating cells Stromal Cells: • Delineation of mechanisms -
Profiling Microdissected Epithelium and Stroma to Model Genomic Signatures for Cervical Carcinogenesis Accommodating for Covariates
Research Article Profiling Microdissected Epithelium and Stroma to Model Genomic Signatures for Cervical Carcinogenesis Accommodating for Covariates David Gius,1 Margo C. Funk,2 Eric Y. Chuang,1 Sheng Feng,3 Phyllis C. Huettner,4 Loan Nguyen,2 C. Matthew Bradbury,1 Mark Mishra,1 Shuping Gao,1 Barbara M. Buttin,2 David E. Cohn,2 Matthew A. Powell,2 Neil S. Horowitz,2 Bradford P. Whitcomb,2 and JanetS. Rader 2 1Radiation Oncology Branch, Center for Cancer Research, National Cancer Institute, NIH, Bethesda, Maryland and 2Division of Gynecologic Oncology, Department of Obstetrics and Gynecology; 3Division of Biostatistics; and 4Lauren V. Ackerman Laboratory of Surgical Pathology, Washington University School of Medicine, St. Louis, Missouri Abstract (CIN 1–3) and finally to squamous cell carcinoma antigen (SCCA) This study is the first comprehensive, integrated approach to have been well characterized. Histologically, CIN 1 consists of examine grade-specific changes in gene expression along the immature basal-type cells involving the lower third of the entire neoplastic spectrum of cervical intraepithelial neoplasia epithelium. In CIN 2, these immature basal-type cells involve more (CIN) in the process of cervical carcinogenesis. This was than the lower third, whereas CIN 3 involves the full thickness of the accomplished by identifying gene expression signatures of epithelium. In addition, higher CIN grades exhibit nuclear crowding, disease progression using cDNA microarrays to analyze RNA pleomorphism, loss of cell polarity, and increased mitotic activity from laser-captured microdissected epithelium and underlying (1). These transitions seemto be well conserved and, as such, stroma from normal cervix, graded CINs, cancer, and patient- provide an intriguing systemto use genomicsto identify the early matched normal cervical tissues. -
Understanding the Immune System: How It Works
Understanding the Immune System How It Works U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES NATIONAL INSTITUTES OF HEALTH National Institute of Allergy and Infectious Diseases National Cancer Institute Understanding the Immune System How It Works U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES NATIONAL INSTITUTES OF HEALTH National Institute of Allergy and Infectious Diseases National Cancer Institute NIH Publication No. 03-5423 September 2003 www.niaid.nih.gov www.nci.nih.gov Contents 1 Introduction 2 Self and Nonself 3 The Structure of the Immune System 7 Immune Cells and Their Products 19 Mounting an Immune Response 24 Immunity: Natural and Acquired 28 Disorders of the Immune System 34 Immunology and Transplants 36 Immunity and Cancer 39 The Immune System and the Nervous System 40 Frontiers in Immunology 45 Summary 47 Glossary Introduction he immune system is a network of Tcells, tissues*, and organs that work together to defend the body against attacks by “foreign” invaders. These are primarily microbes (germs)—tiny, infection-causing Bacteria: organisms such as bacteria, viruses, streptococci parasites, and fungi. Because the human body provides an ideal environment for many microbes, they try to break in. It is the immune system’s job to keep them out or, failing that, to seek out and destroy them. Virus: When the immune system hits the wrong herpes virus target or is crippled, however, it can unleash a torrent of diseases, including allergy, arthritis, or AIDS. The immune system is amazingly complex. It can recognize and remember millions of Parasite: different enemies, and it can produce schistosome secretions and cells to match up with and wipe out each one of them. -
A Novel BCMA/CD3 Bispecific T-Cell Engager for the Treatment
OPEN Leukemia (2017) 31, 1743–1751 www.nature.com/leu ORIGINAL ARTICLE A novel BCMA/CD3 bispecific T-cell engager for the treatment of multiple myeloma induces selective lysis in vitro and in vivo S Hipp1, Y-T Tai2,3, D Blanset4, P Deegen5, J Wahl5, O Thomas5, B Rattel5, PJ Adam1, KC Anderson2,3 and M Friedrich5 B-cell maturation antigen (BCMA) is a highly plasma cell-selective protein that is expressed on malignant plasma cells of multiple myeloma (MM) patients and therefore is an ideal target for T-cell redirecting therapies. We developed a bispecific T-cell engager (BiTE) targeting BCMA and CD3ε (BI 836909) and studied its therapeutic impacts on MM. BI 836909 induced selective lysis of BCMA- positive MM cells, activation of T cells, release of cytokines and T-cell proliferation; whereas BCMA-negative cells were not affected. Activity of BI 836909 was not influenced by the presence of bone marrow stromal cells, soluble BCMA or a proliferation-inducing ligand (APRIL). In ex vivo assays, BI 836909 induced potent autologous MM cell lysis in both, newly diagnosed and relapsed/ refractory patient samples. In mouse xenograft studies, BI 836909 induced tumor cell depletion in a subcutaneous NCI-H929 xenograft model and prolonged survival in an orthotopic L-363 xenograft model. In a cynomolgus monkey study, administration of BI 836909 led to depletion of BCMA-positive plasma cells in the bone marrow. Taken together, these results show that BI 836909 is a highly potent and efficacious approach to selectively deplete BCMA-positive MM cells and represents a novel immunotherapeutic for the treatment of MM.